

U.S. Department of Justice

TJB:rs1
154-730-85

Telephone:
(202) 724-7221

Washington, D.C. 20530

April 16, 1986

Robert C. Gallo, M.D.
Chief, Laboratory of Tumor
Cell Biology
National Cancer Institute
Bethesda, MD 20014

Re: Institut Pasteur v. United States,
Claims Court No. 730-85C

Dear Dr. Gallo:

I have reviewed your proposed letter to Nature. I have a number of suggestions for changes which are incorporated in the enclosed draft. In this draft, deletions are indicated by brackets and additions by underlining (with the exception of a single "not" which was underlined in the original). In addition, the fourth sentence of the original is now the seventh sentence of the draft. With respect to Table I, I have added the notation ND = no data and have placed a second + mark under the EM column for sample No. 2. The purpose of this additional + mark is to show that both HTLV-I and HTLV-III particles were noted in the EM. I have also asked Dr. Sarin to find a sample where reactivity with AIDS sera was tested whether positive or negative. This is important because this test is the basis for the blood test. The dates set forth in this letter will be perceived as our earliest dates; for this reason, the dates must be as early as possible. Another sample before September 1983 showing by EM the presence of an HTLV-III particle would be highly desirable.

Very truly yours,

Thomas J. Byrnes
Attorney
Commercial Litigation Branch
Civil Division

Enclosure

✓ cc: D. G. Grinstead
w/ enclosure